<DOC>
	<DOCNO>NCT02999087</DOCNO>
	<brief_summary>The purpose study demonstrate treatment avelumab combination RT-cetuximab superior standard care ( SOC ) cisplatin-RT and/or SOC RT-cetuximab alone term progression-free survival ( PFS ) front-line patient locally advanced SCCHN .</brief_summary>
	<brief_title>Randomized Trial Avelumab-cetuximab-radiotherapy Versus SOCs LA SCCHN ( REACH )</brief_title>
	<detailed_description>This open-label , randomize , control , multicenter phase III study include 688 patient LA SCCHN ( 420 fit HD cisplatin 268 unfit HD cisplatin ) , histologically confirm receive previous treatment set . The study design primary objective demonstrating treatment avelumab combination cetuximab-RT superior SOC Cisplatin-RT cetuximab-RT alone term PFS . Randomization assign 2 treatment arm cohort 1:1 ratio . In cohort ( fit cisplatin unfit cisplatin ) , randomization stratify 2 establish prognostic factor N stage ( N0-N1 v N2-3 ) p16 expression ( OPC p16+ versus OPC p16- non OPC ) . All patient follow death least 60 month .</detailed_description>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Age ≤ 80 year 2 . Performance Status ECOG 01 3 . Squamous cell carcinoma , previously untreated 4 . Stage III , stage IVa ( i.e . operable , operate ) IVb ( non resectable ) 5 . Oral cavity , oropharynx , hypopharynx larynx 6 . Availability pretreatment tumour tissue sample ( p16 &amp; PD L1 expression , TILs immune landscape ) 7 . Recording alcohol consumption smoke history 8 . Determination patient 's ability receive cisplatin 100 mg /m2 3 cycle ( fit / unfit ) * 9 . Written inform consent Criteria determine patient fit receive high dose cisplatin : Calculated creatinin clearance ≥ 60 mL/min determine modify . method Cockcroft Gault EDTA method Absolute neutrophil count ≥1 500/μL , platelet ≥100 000/μL , hemoglobin ≥ 10 g/dL , aspartate ( AST ) alanine transaminase ( ALT ) less 2 time upper limit normal range ( ULN ) , total bilirubin ≤ 1.5 mg/dL , serum albumin &gt; 35 g/L Peripheral neuropathy &lt; grade 2 No clinical hearing loss ( confirm audiogram ) Cardiac function compatible hyperhydration ; Left ventricular ejection fraction within institutional normal range measure echocardiogram 1 . Nasopharyngeal , paranasal sinus , nasal cavity tumor thyroid cancer 2 . Squamous cell carcinoma involve cervical neck node unknown primary site 3 . Metastatic disease ( stage IVc ) 4 . Viral infection ( HIV , Hepatitis B/C ) 5 . Autoimmune disease 6 . Immunodeficiency immunosuppressive therapy 7 . Active CNS disease 8 . Interstitial lung disease 9 . Active infection 10 . Any prior current treatment invasive head neck cancer . This include limit : prior tyrosine kinase inhibitor , monoclonal antibody , induction chemotherapy , prior surgical resection RT , use investigational agent 11 . Weight loss &gt; 10 % last 4 week ( except renutrition feed tube plan onset treatment ongoing ) 12 . Concurrent treatment systemic anticancer therapy specify protocol 13 . Concomitant treatment drug prohibit medication list live vaccine 14 . History malignancy within last 3 year ( exception situ carcinoma skin carcinoma ) 15 . Significant disease , judgment investigator , result medical interview , physical examination , screen investigation would make patient inappropriate entry trial 16 . Known hypersensitivity reaction study drug 17 . Any social , personal , medical and/or psychological factor ( ) could interfere observance patient protocol and/or followup and/or signature inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Head Neck cancer</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>